Shares of Intellia Therapeutics Inc. , a gene editing company, started trading at $22, above their $18 issue price, in the company’s debut on the Nasdaq Friday. The company sold six million shares to raise about $108 million. The company had priced its shares at the high end of its $16 to $18 range Thursday. The offering was underwritten by Credit Suisse, Jeferies and Leerink Partners.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News